<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vedomostiregmed</journal-id><journal-title-group><journal-title xml:lang="ru">Регуляторные исследования и экспертиза лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Regulatory Research and Medicine Evaluation</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-3062</issn><issn pub-type="epub">3034-3453</issn><publisher><publisher-name>Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30895/1991-2919-2019-9-1-54-63</article-id><article-id custom-type="elpub" pub-id-type="custom">vedomostiregmed-214</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Разработка методик подтверждения подлинности фармацевтических субстанций трипторелина ацетат и гозерелина ацетат  методом ЯМР-спектроскопии</article-title><trans-title-group xml:lang="en"><trans-title>Development of identification test methods for triptorelin acetate and goserelin acetate substances using NMR spectroscopy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1310-4477</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseev</surname><given-names>S. V</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. хим. наук, доцент, ведущий эксперт сектора спектральных методов анализа лаборатории биотехнологических препаратов Испытательного центра экспертизы качества лекарственных средств </p><p>Петровский бульвар, д. 8, стр. 2, Москва, 127051, Российская Федерация</p></bio><bio xml:lang="en"><p>Cand. Sci. (Chem.), Leading Expert of the Spectral Methods Sector of the Laboratory of Biotechnological Products of the Testing Centre for Evaluation of Medicinal Products’ Quality </p><p>8/2 Petrovsky Blvd, Moscow 127051, Russian Federation</p></bio><email xlink:type="simple">MoiseevSV@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9133-0835</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьмина</surname><given-names>Н. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuz’mina</surname><given-names>N. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р хим. наук, начальник сектора спектральных методов анализа лаборатории биотехнологических препаратов Испытательного центра экспертизы качества лекарственных средств </p><p>Петровский бульвар, д. 8, стр. 2, Москва, 127051, Российская Федерация</p></bio><bio xml:lang="en"><p>Dr. Sci. (Chem.), Head of the Spectral Methods Sector of the Laboratory of Biotechnological Products of the Testing Centre for Evaluation of Medicinal Products’ Quality </p><p>8/2 Petrovsky Blvd, Moscow 127051, Russian Federation</p></bio><email xlink:type="simple">KuzminaN@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8752-5245</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лутцева</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Luttseva</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. фарм. наук, начальник Испытательного центра экспертизы качества лекарственных средств </p><p>Петровский бульвар, д. 8, стр. 2, Москва, 127051, Российская Федерация</p></bio><bio xml:lang="en"><p>Cand. Sci. (Pharm.), Head of the Testing Centre for Evaluation of Medicinal Products’ Quality </p><p>8/2 Petrovsky Blvd, Moscow 127051, Russian Federation</p></bio><email xlink:type="simple">Lutceva@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения»<country>Россия</country></aff><aff xml:lang="en">Scientific Centre for Expert Evaluation of Medicinal Products<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>20</day><month>02</month><year>2019</year></pub-date><volume>9</volume><issue>1</issue><fpage>54</fpage><lpage>63</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Моисеев С.В., Кузьмина Н.Е., Лутцева А.И., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Моисеев С.В., Кузьмина Н.Е., Лутцева А.И.</copyright-holder><copyright-holder xml:lang="en">Moiseev S.V., Kuz’mina N.E., Luttseva A.I.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.vedomostincesmp.ru/jour/article/view/214">https://www.vedomostincesmp.ru/jour/article/view/214</self-uri><abstract><p>Работа является продолжением исследования по внедрению метода ЯМР-спектроскопии в контроль качества фармацевтических субстанций природных пептидных гормонов и их синтетических аналогов. Цель работы: разработка методик подтверждения подлинности фармацевтических субстанций трипторелина ацетата и гозерелина ацетата методом ЯМР-спектроскопии без использования стандартных образцов для их дальнейшего использования в фармакопейном анализе. Материалы и методы: при разработке методики были использованы методы двумерной ЯМР-спектроскопии (1H-1H gCOSY, 1H-13C gHSQC, 1H-13C gHMBC). Результаты: в процессе исследования проведено соотнесение сигналов 1Н и 13С ЯМР-спектров конкретному структурному фрагменту молекулы, определен аминокислотный состав и установлена аминокислотная последовательность каждого олигопептида. Выводы: составлена таблица структурного соотнесения сигналов спектров ЯМР, позволяющая использовать метод ЯМР для подтверждения подлинности фармацевтических субстанций трипторелина ацетат и гозерелина ацетат без использования фармакопейных стандартных образцов. Подобраны оптимальные температурные условия для регистрации 13C ЯМР-спектров (27 и 50 °С для трипторелина ацетата и гозерелина ацетата соответственно). Показана целесообразность использования в фармакопейном анализе методики подтверждения подлинности, основанную на методе 13C ЯМР-спектроскопии.</p></abstract><trans-abstract xml:lang="en"><p>The work is a continuation of the research on the use of NMR spectroscopy in the quality control of natural peptide hormone-based active substances and their synthetic analogues. The aim of the paper was to develop identification test methods for triptorelin acetate and goserelin acetate substances using NMR spectroscopy that does not require reference standards ‒ with the aim of using the newly developed test methods in pharmacopoeial analysis. Materials and methods: the procedure was developed using two-dimensional NMR spectroscopy (1H-1H gCOSY, 1H-13C gHSQC, 1H-13C gHMBC). Results: thestudy made it possible to assign 1H and 13C NMR signals to a specific molecular fragment, and to determine the amino acid composition of each oligopeptide. Conclusions: the authors drew up a table showing structural assignment of NMR signals, which makes it possible to use the NMR method for identification testing of triptorelin acetate and goserelin acetate substances without the use of pharmacopoeial reference standards. The study helped to determine the optimal temperature conditions for recording 13C NMR spectra (27 °С and 50 °С for triptorelin acetate and goserelin acetate, respectively). It was demonstrated that 13C NMR spectroscopy could be used for identification testing in pharmacopoeial analysis.  </p></trans-abstract><kwd-group xml:lang="ru"><kwd>трипторелина ацетат</kwd><kwd>гозерелина ацетат</kwd><kwd>ЯМР-спектроскопия</kwd><kwd>подлинность</kwd><kwd>внутримолекулярное взаимодействие</kwd></kwd-group><kwd-group xml:lang="en"><kwd>triptorelin acetate</kwd><kwd>goserelin acetate</kwd><kwd>NMR spectroscopy</kwd><kwd>identification</kwd><kwd>intramolecular interaction</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00154-19-00 на проведение прикладных научных исследований (номер государственного учета НИР AAAAA18-118021590049-0).</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>The study reported in this publication was carried out as part of a publicly funded research project No. 056-00023-18-02 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&amp;D public accounting No. AAAA-A18-118021590049-0).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Кузьмина НЕ, Моисеев СВ, Крылов ВИ, Яшкир ВА, Меркулов ВА. Разработка методики подтверждения подлинности фармацевтической субстанции «бусерелина ацетат» методом ЯМР-спектроскопии без использования фармакопейного стандартного образца. Антибиотики и химиотерапия. 2017;62(9–10):40–6.</mixed-citation><mixed-citation xml:lang="en">Kuz’mina NE, Moiseev SV, Krylov VI, Yashkir VA, Merkulov VA. Development of a procedure for the identification of pharmaceutical substance buserelin acetate by NMR spectroscopy without using pharmacopoeia reference standard. Antibiotiki i Khimioterapiya 2017; 62(9-10): 40-46 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Кузьмина НЕ, Моисеев СВ, Крылов ВИ, Дерябин АС, Яшкир ВА, Меркулов ВА. Валидация методики подтверждения подлинности фармацевтической субстанции «бусерелина ацетат» методом ЯМР-спектроскопии. Химико-фармацевтический журнал. 2018;52(2):48–53. https://doi.org/10.30906/0023-1134-2018-52-2-48-53 https://doi.org/10.1007/s11094-018-1783-8</mixed-citation><mixed-citation xml:lang="en">Kuz’mina NE, Moiseev SV, Krylov VI, Deryabin AS, Yashkir VA, Merkulov VA. Validation of an NMR-Spectroscopic Method for Authenticity Confirmation of Buserelin Acetate Pharmaceutical Substance. Pharmaceutical Chemistry Journal. 2018; 52(2): 48-53; (in Russ.). https://doi.org/10.30906/0023-1134-2018-52-2-48-53.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ковалева СВ, Исаева ИВ, Лутцева АИ, Аладышева ЖИ, Пихтарь АВ. Проблемы стандартизации гормональных препаратов пептидно-белковой природы. Российский химический журнал. 2005;49(1):135–45.</mixed-citation><mixed-citation xml:lang="en">Kovaleva SV, Isaeva IV, Lutseva AI, Aladysheva GI, Pikhtar AV. Problems for standardization of hormonal preparations of protein-peptide nature. Russian Journal of General Chemistry. 2005; XLIX(1):135-145 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Матвеев БП. Роль трипторелина (диферелин) в лечении рака предстательной железы. Онкоурология. 2008;(4):53–6.</mixed-citation><mixed-citation xml:lang="en">Matveyev BP. The Role of Triptorelin (Diphereline) in the Treatment of Prostate Cancer. Oncourology. 2008; (4): 53-56 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Frampton JE. Triptorelin: a review of its use as an adjuvant anticancer therapy in early breast cancer. Drugs. 2017;77(18):2037–48. https://doi.org/10.1007/s40265-017-0849-3</mixed-citation><mixed-citation xml:lang="en">Frampton JE. Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer. Drugs. 2017; 77(18):2037-2048.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Venturelli M, Guaitoli G, Omarini C, Moscetti L. Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer. Breast Cancer (Dove Med Press). 2018;(10):39–49. https://doi.org/10.2147/BCTT.S137508</mixed-citation><mixed-citation xml:lang="en">Venturelli M, Guaitoli G, Omarini C, Moscetti L. Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer. Breast Cancer: Targets and Therapy 2018; 10: 39-49.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Choktanasiri W, Boonkasemsanti W, Sittisomwong T, Kunathikom S, Suksompong S, Udomsubpayakul U, Rojanasakul A. Long-acting triptorelin for the treatment of endometriosis. Int J Gynaecol Obstet. 1996;54(3):237–43. PMID:8889631</mixed-citation><mixed-citation xml:lang="en">Choktanasiri W, Boonkasemsanti W, Sittisomwong T, Kunathikom S, Suksompong S, Udomsubpayakul U, Rojanasakul A. Long-acting triptorelin for the treatment of endometriosis. Int. J Gynaecol Obstet. 1996; 54(3):237-43.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Высоцкая НВ, Максимов КВ. Адъювантная эндокринотерапия рака молочной железы у группы больных пременопаузного возраста. Опухоли женской репродуктивной системы. 2007;(1–2):45–7.</mixed-citation><mixed-citation xml:lang="en">Vysotskaya IV, Maksimov KV. Adjuvant endocrine therapy for breast cancer in a group of premenopausal patients. Opukholy Zhenskoi Reproduktivnoi Systemy. 2007; (102): 45-47 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wu S, Li Q, Zhu Y, Sun J, Li F, Lin H, Guan X, He Z. Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor: a retrospective matched case-control study. Cancer Biother Radiopharm. 2013;28(10):697–702. https://doi.org/10.1089/cbr.2012.1436</mixed-citation><mixed-citation xml:lang="en">Sangang Wu, Qun Li, Yuliang Zhu, Jiayuan Sun, Fengyan Li, Huanxin Lin, Xunxing Guan, and Zhenyu He. Role of Goserelin in Combination with Endocrine Therapy for the Treatment of Advanced Breast Cancer in Premenopausal Women Positive for Hormone Receptor: A Retrospective Matched Case–Control Study Cancer Biother Radiopharm. 2013; 28(10): 697–702.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gottlieb HE, Kotlyar V, Nudelman A. NMR chemical shifts of common laboratory solvents as trace impurities. J Org Chem. 1997;62(21):7512–5. https://doi.org/10.1021/jo971176v</mixed-citation><mixed-citation xml:lang="en">Gottlieb HE, Kotlyar V, and Nudelman A. NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities. J. Org. Chem. 1997; 62(21): 7512 - 7515.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">General monograph 2.2.64 Peptide identification by nuclear magnetic resonace. in: European Pharmacopoeia, 9th ed. V.1. Strasbourg: European Department for the Quality of Medicines &amp; Health Care; 2016. p. 112.</mixed-citation><mixed-citation xml:lang="en">General monograph 2.2.64 Peptide identification by nuclear magnetic resonace. in: European Pharmacopoeia, 9th ed. V.1. Strasbourg: European Department for the Quality of Medicines &amp; Health Care; 2016. p. 112.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
